Context: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disorder worldwide, yet pharmacological treatment options remain limited. Therapeutic agents that modulate both metabolic and hepatic pathological pathways are urgently needed. Aims: To identify chemical constituents from the ethanolic extract of Clinacanthus nutans and predict their interactions with validated molecular targets implicated in MASLD using in silico methodologies. Methods: Metabolite profiling was conducted using ultra-high-performance liquid chromatography–mass spectrometry (UHPLC–MS). Identified compounds were evaluated for drug-likeness based on Lipinski, Ghose, and Veber criteria. Compounds meeting these criteria were subjected to ADMET profiling and molecular docking against 20 MASLD-associated targets using validated docking protocols. The potential compound underwent molecular dynamics analysis. Results: Seventeen compounds were identified from the C. nutans extract. Six metabolites, along with stearidonic acid, demonstrated favorable pharmacokinetic properties. Among these, a thiophene-based benzoic acid derivative and tagalsin Q exhibited strong binding affinities toward CCR2, ChREBP, and SGLT2, with interaction profiles comparable to native ligands. Conclusions: Metabolites of C. nutans possess predicted bioactivity against CCR2, ChREBP, and SGLT2, supporting their potential utility as multi-target phytotherapeutic agents for MASLD.
Background: High levels of physical activity are key to improving health outcomes, yet many people fail to take action. Using pedometers to target steps per day and providing financial incentives is a simple and scalable approach to promoting public health. However, conventional pedometers do not account for “intensity” and “duration,” making it challenging to efficiently increase people’s moderate-to-vigorous physical activity (MVPA), which is expected to improve health outcomes. Based on these rationales, we developed a smartphone app that sets step cadence as a goal (defined as a daily challenge of walking more than 1500 steps in 15 minutes twice a day, which is a heuristic threshold for moderate physical activity) and provides financial incentive when the challenge is met. Objective: This study aimed to evaluate the feasibility of our novel app and explore whether its use can increase users’ daily MVPA. Methods: A single-arm pre-post study evaluated the feasibility and efficacy of the app. A total of 15 participants used app 1 (an app without financial incentives) for the first period (4 weeks) and then switched to app 2 (an app with financial incentives) for the second period (4 weeks). The primary outcome was the difference between the first and second periods in the number of successful challenge attempts per week. Secondary outcomes were differences between the first and second periods in daily steps and distance walked. Exploratory outcomes included the difference between the first and second periods in daily “heart points” as measured by Google Fit, a publicly available app that measures users’ daily MVPA. Results: The number of successful challenge attempts per week increased significantly compared to the first period (5.6 times per week vs 0.7 times per week; P<.001). Although not statistically significant, there was a trend toward an increase in the mean steps per day and distance walked per day (6586 steps per day vs 5950 steps per day; P=.19; and 4.69 km per day vs 3.85 km per day; P=.09, respectively). An exploratory end point examining daily MVPA by “heart points” collected from Google Fit also showed a significant increase compared to the first period (22.7 points per day vs 12.8 points per day; P=.02). Conclusions: Our app using step cadence as a goal and providing financial incentives seemed feasible and could be an effective app to increase users’ daily MVPA. Based on the results of this study, we are motivated to conduct a confirmatory study with a broader and larger number of participants. Trial Registration: UMIN 000050518; https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000057420
The phytochemical profile and hepatoprotective, antioxidant, and lipid-modulating effects of the ethanolic extract of Clinacanthus nutans leaves were examined in male C57BL/6 mice fed a cholesterol-supplemented western diet. After 15 weeks of feeding, the untreated mice developed steatosis, lobular inflammation, and ballooning hepatocytes, with NAFLD activity scores ≥5, indicative of metabolic dysfunction-associated steatohepatitis (MASH). Treatment with Clinacanthus nutans extract at doses of 100, 200, and 400 mg/kg from week 8 to 15 significantly reduced the liver-to-body weight ratio and NAFLD activity score, with dose-dependent histological improvement, particularly reduced lobular inflammation. AST, ALT, and hepatic malondialdehyde levels were significantly lowered in the treated groups, with effects exceeding those of atorvastatin. However, Clinacanthus nutans extract did not attenuate the elevated LDL-to-HDL ratio. In conclusion, Clinacanthus nutans extract effectively prevented the progression from simple steatosis to steatohepatitis, likely through antioxidative mechanisms attributable to its high tannin content.
1 December 2019 in Biological and Pharmaceutical Bulletin
We evaluated the effects of anticholinergic drugs principally used for the therapy of overactive bladder (OAB) on the activity of P-glycoprotein, an efflux transport protein, in Caco-2 cells. The time-dependent changes in the fluorescence of residual rhodamine 123, a P-glycoprotein activity marker, in the apical region of Caco-2 cells were measured in the presence of anticholinergic drugs using time-lapse confocal laser scanning microscopy. The effect of anticholinergic drugs on human P-glycoprotein ATPase activity was also measured. The fluorescence of residual rhodamine 123 in untreated Caco-2 cells decreased over time. The gradual decrease in the fluorescence was significantly inhibited by treatment with cyclosporine A, darifenacin, and trospium. In contrast, oxybutynin, N-desethyl-oxybutynin (DEOB), propiverine, and its active metabolites (M-1, M-2), imidafenacin, solifenacin, or tolterodine had little effect on the efflux of rhodamine 123. P-Glycoprotein ATPase activity was increased by darifenacin. Darifenacin and trospium reduced the rhodamine 123 transfer across the apical cell membrane. These data suggest that darifenacin and trospium interact with P-glycoprotein. Additionally, darifenacin influenced P-glycoprotein ATPase activity. These results suggest that darifenacin may be a substrate of P-glycoprotein. This study is the first paper to test simultaneously the effects of 10 anticholinergic drugs used currently for the therapy of OAB, on the P-glycoprotein.
26 July 2017 in Immunopharmacology and Immunotoxicology
Objective: In this study, we aimed to study the effects of ICI204,448, naloxone methiodide and levocetirizine on the scratching behavior induced by intradermal injection of a ?-opioid antagonist, nor-binaltorphimine (nor-BNI), into the rostral back of ICR mice were investigated. Materials and methods: Male ICR mice weighing 30?35 g were used. The number of scratching episodes were counted for 60 min after i.d. injection of nor-BNI. Results: nor-BNI dose dependently increased in the number of scratching episodes in ICR mice. nor-BNI-induced scratching behavior was inhibited by not only nalfurafine but also ICI204,448, a peripherally selective ?-opioid agonist. Naloxone and naloxone methiodide, a peripherally restricted ?-opioid antagonist, also inhibited nor-BNI-induced scratching behavior. Scratching behavior induced by nor-BNI was inhibited by chlorpheniramine as well as levocetirizine, a third-generation H1 antagonist that does not cross into the CNS. Conclusion: These results suggest that scratching behavior induced by this ?-opioid antagonist, nor-BNI, is related to not only central but also peripheral opioid and H1 receptors.